{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:56:05Z","timestamp":1773939365953,"version":"3.50.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bulcan.2025.05.017","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:12:58Z","timestamp":1756897978000},"page":"512-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommandations du GBMHM et du Fi-LMC pour le diagnostic et le suivi mol\u00e9culaire des patients atteints de leuc\u00e9mie my\u00e9lo\u00efde chronique"],"prefix":"10.1016","volume":"113","author":[{"given":"Jean-Michel","family":"Cayuela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Dulucq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Hayette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Nibourel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck-Emmanuel","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Raimbault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Sloma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"R\u00e9a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.05.017_bib0490","first-page":"103424","article-title":"Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic\/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH)","volume":"71","author":"Decamp","year":"2023","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0495","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020\u00a0recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0500","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2018.208801","article-title":"Poor prognosis of chromosome 7\u00a0clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia","volume":"104","author":"Bidet","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0505","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1\u00a0transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0510","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/gcc.22263","article-title":"Molecular characterization and follow-up of five CML patients with new BCR-ABL1\u00a0fusion transcripts","volume":"54","author":"Huet","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0515","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41375-024-02314-7","article-title":"The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1\u00a0isoforms are resistant to asciminib","volume":"38","author":"Leske","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0520","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1002\/cncr.31408","article-title":"The impact of BCR-ABL1\u00a0transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia","volume":"124","author":"Ercaliskan","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0525","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0530","first-page":"186","article-title":"An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders","volume":"8","author":"Cross","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0535","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1\u00a0Concerted Action: investigation of minimal residual disease in acute leukemia","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0540","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0545","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0550","doi-asserted-by":"crossref","first-page":"E623","DOI":"10.1002\/ajh.24865","article-title":"Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients","volume":"92","author":"Mologni","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0555","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.exphem.2017.05.007","article-title":"Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia","volume":"53","author":"Sloma","year":"2017","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0560","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0565","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41586-025-08817-2","article-title":"Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia","volume":"640","author":"Kamizela","year":"2025","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bulcan.2025.05.017_bib0570","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ajh.27553","article-title":"Mutation of epigenetic regulators at diagnosis is an independent predictor of tyrosine kinase inhibitor treatment failure in chronic myeloid leukemia: a report from the RESIDIAG study","volume":"100","author":"Guerineau","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0575","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0580","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0585","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0590","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","article-title":"ASXL1\u00a0mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Sch\u00f6nfeld","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0595","first-page":"2380","article-title":"Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention","volume":"108","author":"Shanmuganathan","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0600","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1\u00a0mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0605","first-page":"942","article-title":"Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia","volume":"109","author":"Behrens","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0610","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0615","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Adnan Awad","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0620","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bulcan.2019.05.011","article-title":"Recommendations from the French CML Study group (Fi-LMC) for BCR-ABL1\u00a0kinase domain mutation analysis in chronic myeloid leukemia","volume":"107","author":"Cayuela","year":"2020","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0625","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","article-title":"Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors","volume":"104","author":"Nteliopoulos","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0630","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.2147\/OTT.S257661","article-title":"Integrative genomic analysis reveals cancer-associated gene mutations in chronic myeloid leukemia patients with resistance or intolerance to tyrosine kinase inhibitor","volume":"13","author":"Wu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0635","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-022-00742-1","article-title":"Prognostic impact of ASXL1\u00a0mutations in chronic phase chronic myeloid leukemia","volume":"12","author":"Bidikian","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0640","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/bloodadvances.2023012127","article-title":"Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes","volume":"8","author":"Perusini","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0645","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/s41467-021-23097-w","article-title":"Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia","volume":"12","author":"Ochi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0650","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41375-024-02204-y","article-title":"Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry","volume":"38","author":"Brioli","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0655","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017\u00a0ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0660","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022\u00a0recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0665","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9\u00a0% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0670","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1038\/s41375-020-0751-y","article-title":"Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia","volume":"34","author":"Thomson","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0675","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jmoldx.2022.07.004","article-title":"Fusion gene detection and quantification by asymmetric capture sequencing (aCAP-Seq)","volume":"24","author":"Gricourt","year":"2022","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0680","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jmoldx.2022.04.004","article-title":"RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia","volume":"24","author":"Shanmuganathan","year":"2022","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0685","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0690","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0695","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/bjh.17521","article-title":"Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1\u00a0in chronic myeloid leukaemia in an international interlaboratory study","volume":"194","author":"Scott","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0700","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients","volume":"25","author":"Nicolini","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0705","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0710","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0715","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1097\/HS9.0000000000000658","article-title":"Improvement of standardization of molecular analyses in hematology: the 10-year GBMHM French experience","volume":"5","author":"Alary","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0720","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0725","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00432-014-1746-8","article-title":"Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase","volume":"140","author":"Lauseker","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0730","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study group","volume":"124","author":"Rea","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0735","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0740","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International genetic reference panel for quantitation of BCR-ABL mRNA","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0745","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/leu.2016.90","article-title":"Development and evaluation of a secondary reference panel for BCR-ABL1\u00a0quantification on the International Scale","volume":"30","author":"Cross","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0750","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41375-022-01607-z","article-title":"Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study","volume":"36","author":"White","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0755","series-title":"ISO 15189:2022\u00a0Medical Laboratories\u2013Requirements for quality and competence has been published","author":"Uraine","year":"2023"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0760","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","article-title":"Guidelines for the measurement of BCR-ABL1\u00a0transcripts in chronic myeloid leukaemia","volume":"153","author":"Foroni","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0765","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/leu.2014.217","article-title":"A certified plasmid reference material for the standardisation of BCR-ABL1\u00a0mRNA quantification by real-time quantitative PCR","volume":"29","author":"White","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0770","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.3324\/haematol.2022.280811","article-title":"Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2\u00a0trial","volume":"107","author":"Dulucq","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0775","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.3324\/haematol.2022.280740","article-title":"Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission","volume":"107","author":"Dulucq","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0780","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0785","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10\u00a0% BCR-ABL1\u00a0after 3\u00a0months of imatinib depends on the rate of BCR-ABL1\u00a0decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0790","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.2020005514","article-title":"Early BCR-ABL1\u00a0kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","volume":"137","author":"Shanmuganathan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0795","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1007\/s00432-021-03569-8","article-title":"Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1\u00a0fusion transcripts: recommendations by the EUTOS cooperative network","volume":"147","author":"Schafer","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0800","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1097\/HS9.0000000000000496","article-title":"Digital PCR for BCR-ABL1\u00a0quantification in CML: current applications in clinical practice","volume":"4","author":"Kockerols","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0805","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/s41375-020-0882-1","article-title":"Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission","volume":"34","author":"Machova Polakova","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0810","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41375-019-0647-x","article-title":"Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission","volume":"34","author":"Pagani","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0815","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0820","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2\u00a0or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0825","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0830","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.2023022538","article-title":"BCR::ABL1\u00a0kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib","volume":"144","author":"Leyte-Vidal","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0835","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-Abl1\u00a0mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0840","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2016.145888","article-title":"Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia","volume":"101","author":"Baer","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0845","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR-ABL1\u00a0kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0850","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0855","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12885-016-2635-0","article-title":"In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1\u00a0at the time of warning may allow sensitive detection of emerging drug-resistant mutants","volume":"16","author":"Soverini","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0860","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1038\/s41375-022-01660-8","article-title":"Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1\u00a0kinase domain mutations in chronic myeloid leukemia","volume":"36","author":"Soverini","year":"2022","journal-title":"Leukemia"},{"issue":"Suppl. 6","key":"10.1016\/j.bulcan.2025.05.017_bib0865","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.htct.2023.12.007","article-title":"Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction","volume":"46","author":"Mu","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0870","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-024-06142-8","article-title":"Asciminib resistance of a new BCR::ABL1\u00a0p.I293_K294insSSLRD mutant detected in a Ph+ALL patient","author":"Cullot","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0875","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1182\/blood-2011-05-349191","article-title":"The BCR-ABL35INS insertion\/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"118","author":"O\u2019Hare","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2025.05.017_bib0880","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0885","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0890","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-020-01098-w","article-title":"BCR-ABL1\u00a0compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS","volume":"35","author":"Soverini","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0895","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.3324\/haematol.2017.176347","article-title":"BCR-ABL1\u00a0compound mutants display differential and dose-dependent responses to ponatinib","volume":"103","author":"Byrgazov","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0900","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1\u00a0compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0905","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1002\/ajh.27095","article-title":"Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1\u00a0fusion gene in Ph-positive leukemias","volume":"99","author":"Sponseiler","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0910","series-title":"Chronic myeloid Leukemia in children. Paediatric Tumours part A vol. 7","first-page":"4","author":"Millot","year":"2023"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0915","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3390\/cancers13040798","article-title":"Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia","volume":"13","author":"Suttorp","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0920","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-022-05024-1","article-title":"Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course","volume":"102","author":"Delehaye","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0925","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.16241","article-title":"Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children","volume":"188","author":"Kn\u00f6fler","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0930","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0935","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0940","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2019.03.020","article-title":"Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia","volume":"115","author":"Millot","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0945","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41375-023-01822-2","article-title":"Management of children and adolescents with chronic myeloid leukemia in blast phase: international pediatric CML expert panel recommendations","volume":"37","author":"Sembill","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0950","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2020.06.024","article-title":"Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: a report from the I-CML-Ped Study","volume":"137","author":"Meyran","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0955","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/cncr.30767","article-title":"Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: the experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents","volume":"123","author":"Millot","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0960","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3390\/cancers14071712","article-title":"The cytogenetic landscape of pediatric chronic myeloid leukemia diagnosed in chronic phase","volume":"14","author":"Karow","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0965","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic\u00a0neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.05.017_bib0485","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3324\/haematol.2009.019224","article-title":"Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia","volume":"95","author":"Suttorp","year":"2010","journal-title":"Haematologica"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125003388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125003388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:36:51Z","timestamp":1773934611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125003388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0007455125003388"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.05.017","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations du GBMHM et du Fi-LMC pour le diagnostic et le suivi mol\u00e9culaire des patients atteints de leuc\u00e9mie my\u00e9lo\u00efde chronique","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}